Scinai Immunotherapeutics Ltd. Stock: price and insider trades · United States
US·Mcap US$1.7M
Scinai Immunotherapeutics Ltd.: what insiders have been doing
Insider filings for Scinai Immunotherapeutics Ltd. are scarce in the SEC (Form 4) feed, the latest one published on 18 June 2026. This page will fill in as new trades are disclosed. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.23
Analyst consensus
Income statement
RevenueUS$1.3M
Gross profit-US$2.7M-202% margin
EBITDA-US$6.5M-498% margin
Net income-US$7.3M-174.8% margin
Valuation
PER (trailing)0.0x
P/Book0.1x
Beta2.13
Balance sheet & cash
Market capUS$1.7M
Total debtUS$2.3M
Free Cash Flow-US$6.1M
Debt / Equity31%
Profitability & ownership
ROE-26.5%
ROA-36.2%
% insiders14.2%
% institutions3.3%
Last declaration on 18 June 2026
Declarations1 total
- 120,000,000 sharesOrdinary SharesSEC:0001178913-26-003261:0
1 of 1 declaration
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. is a company focused on developing immunotherapeutic treatments. It is listed on NASDAQ.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
